Pre-made Lorvotuzumab Mertansine benchmark antibody (Whole mAb ADC, anti-NCAM1 therapeutic antibody, Anti-CD56/MSK39/NCAM Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Lorvotuzumab Mertansine benchmark antibody (Whole mAb ADC, anti-NCAM1 therapeutic antibody, Anti-CD56/MSK39/NCAM Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lorvotuzumab mertansine (IMGN91) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN91), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-899-1mg	1mg	Inquiry
GMP-Bios-INN-899-10mg	10mg	Inquiry
GMP-Bios-INN-899-100mg	100mg	Inquiry
GMP-Bios-INN-899-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lorvotuzumab Mertansine Biosimilar, Whole Mab Adc, Anti-Ncam1 Antibody: Anti-CD56/MSK39/NCAM therapeutic antibody Drug Conjugate
INN Name	Lorvotuzumab Mertansine
Target	NCAM1
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	ImmunoGen Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0